SPR Therapeutics® Secures $25 Million in Series C FinancingFunding will support commercialization of SPRINT® PNS System, a non-opioid neurostimulation pain-relief therapy for chronic and acute pain

Story excerpt provided by Markets Insider.

CLEVELAND, Sept. 12, 2017 (GLOBE NEWSWIRE) — SPR Therapeutics, Inc., (SPR) a private medical device company that has developed a novel neurostimulation technology for chronic and acute pain, announced today the completion of $25 million in Series C Financing.  The investment will be used to commercialize its FDA-cleared SPRINT® Peripheral Nerve Stimulation (PNS) System and to fund additional research across multiple indications including post-surgical acute pain and chronic low back pain.  A prominent family office and Frontcourt Ventures led the round.

Click here to read the complete article.

Originally published September 12, 2017.